- Indication
- Overactive bladder syndrome
- RAG rating
- Green
- Document type
- NICE technology appraisal
- Place
- Hertfordshire and West Essex ICB
- Output type
- Pharmacy / Prescribing
Vibegron
Vibegron is recommended in line with NICE TA9991 as an option for treating the symptoms of overactive bladder syndrome in adults. It is only recommended if antimuscarinic medicines are not suitable, do not work well enough or have unacceptable side effects.
Vibegron works in a similar way to mirabegron. Vibegron is a recently launched medicine in the UK therefore long-term clinical trial and real-world data is limited. The SPC for vibegron does not list hypertension as a contraindication or under special warnings and precautions for use or include recommendations for blood pressure monitoring. Hypertension was the most common adverse event reported in the pivotal extension study1. Consider appropriate patient counselling, monitoring and reporting adverse effects using the MHRA Yellow Card2 reporting site as necessary.
Refer to SPC3 for full prescribing information.
1. NICE TA999 Vibegron for treating symptoms of overactive bladder syndrome https://www.nice.org.uk/guidance/ta999
2. MHRA: Yellow Card reporting site. https://yellowcard.mhra.gov.uk/
3. SPC Obgemsa® https://www.medicines.org.uk/emc/product/15962/smpc